Archives of Plastic Surgery

  • 제48권6호
  • /
  • Pages.703-713
  • /
  • 2021
  • /
  • 2234-6163(pISSN)
  • /
  • 2234-6171(eISSN)
대한성형외과학회 (Korean Society of Plastic and Reconstructive Surgeons)
권호 표지
DOI QR코드

DOI QR Code

Clinical and preclinical tolerance protocols for vascularized composite allograft transplantation

  • Yang, Jerry Huanda (Division of Plastic and Reconstructive Surgery, University of Colorado School of Medicine) ;
  • Johnson, Ariel C. (Division of Plastic and Reconstructive Surgery, University of Colorado School of Medicine) ;
  • Colakoglu, Salih (Department of Plastic and Reconstructive Surgery, The Johns Hopkins Hospital) ;
  • Huang, Christene A. (Division of Plastic and Reconstructive Surgery, University of Colorado School of Medicine) ;
  • Mathes, David Woodbridge (Division of Plastic and Reconstructive Surgery, University of Colorado School of Medicine)
  • 투고 : 2021.05.04
  • 심사 : 2021.09.06
  • 발행 : 2021.11.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The field of vascularized composite allografts (VCAs) has undergone significant advancement in recent decades, and VCAs are increasingly common and accepted in the clinical setting, bringing hope of functional recovery to patients with debilitating injuries. A major obstacle facing the widespread application of VCAs is the side effect profile associated with the current immunosuppressive regimen, which can cause a wide array of complications such as infection, malignancy, and even death. Significant concerns remain regarding whether the treatment outweighs the risk. The potential solution to this dilemma would be achieving VCA tolerance, which would allow recipients to receive allografts without significant immunosuppression and its sequelae. Promising tolerance protocols are being studied in kidney transplantation; four major trials have attempted to withdraw immunosuppressive treatment with various successes. The common theme in all four trials is the use of radiation treatment and donor cell transplantation. The knowledge gained from these trials can provide valuable insight into the development of a VCA tolerance protocol. Despite similarities, VCAs present additional barriers compared to kidney allografts regarding tolerance induction. VCA donors are likely to be deceased, which limits the time for significant pre-conditioning. VCA donors are also more likely to be human leukocyte antigen-mismatched, which means that tolerance must be induced across major immunological barriers. This review also explores adjunct therapies studied in large animal models that could be the missing element in establishing a safe and stable tolerance induction method.

키워드

참고문헌

  1. Shores JT, Brandacher G, Lee WP. Hand and upper extremity transplantation: an update of outcomes in the worldwide experience. Plast Reconstr Surg 2015;135:351e-360e. https://doi.org/10.1097/PRS.0000000000000892
  2. Sosin M, Rodriguez ED. The face transplantation update: 2016. Plast Reconstr Surg 2016;137:1841-50. https://doi.org/10.1097/PRS.0000000000002149
  3. Molitor M. Transplantation of vascularized composite allografts: review of current knowledge. Acta Chir Plast 2016;58:18-28.
  4. Colakoglu S, Tebockhorst S, Mathes DW. Is vascularized composite allograft transplantation experimental or an accepted surgical procedure: results from a national survey. J Reconstr Microsurg 2020;36:276-80. https://doi.org/10.1055/s-0039-1701029
  5. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349:931-40. https://doi.org/10.1056/NEJMoa021744
  6. Gallagher MP, Kelly PJ, Jardine M, et al. Long-term cancer risk of immunosuppressive regimens after kidney transplantation. J Am Soc Nephrol 2010;21:852-8. https://doi.org/10.1681/ASN.2009101043
  7. Diaz-Siso JR, Sosin M, Plana NM, et al. Face transplantation: complications, implications, and an update for the oncologic surgeon. J Surg Oncol 2016;113:971-5. https://doi.org/10.1002/jso.24211
  8. Hart A, Smith JM, Skeans MA, et al. Kidney. Am J Transplant 2016;16(Suppl 2):11-46.
  9. Rifkin WJ, Manjunath AK, Kantar RS, et al. A comparison of immunosuppression regimens in hand, face, and kidney transplantation. J Surg Res 2021;258:17-22. https://doi.org/10.1016/j.jss.2020.08.006
  10. Petruzzo P, Lanzetta M, Dubernard JM, et al. The International Registry on Hand and Composite Tissue Transplantation. Transplantation 2010;90:1590-4. https://doi.org/10.1097/TP.0b013e3181ff1472
  11. Dubernard JM, Lengele B, Morelon E, et al. Outcomes 18 months after the first human partial face transplantation. N Engl J Med 2007;357:2451-60. https://doi.org/10.1056/NEJMoa072828
  12. Schneeberger S, Gorantla VS, van Riet RP, et al. Atypical acute rejection after hand transplantation. Am J Transplant 2008;8:688-96. https://doi.org/10.1111/j.1600-6143.2007.02105.x
  13. Krezdorn N, Lian CG, Wells M, et al. Chronic rejection of human face allografts. Am J Transplant 2019;19:1168-77. https://doi.org/10.1111/ajt.15143
  14. Petruzzo P, Kanitakis J, Testelin S, et al. Clinicopathological findings of chronic rejection in a face grafted patient. Transplantation 2015;99:2644-50. https://doi.org/10.1097/TP.0000000000000765
  15. Kanitakis J, Petruzzo P, Badet L, et al. Chronic rejection in human vascularized composite allotransplantation (hand and face recipients): an update. Transplantation 2016;100:2053-61. https://doi.org/10.1097/TP.0000000000001248
  16. Yen EF, Hardinger K, Brennan DC, et al. Cost-effectiveness of extending Medicare coverage of immunosuppressive medications to the life of a kidney transplant. Am J Transplant 2004;4:1703-8. https://doi.org/10.1111/j.1600-6143.2004.00565.x
  17. Issa F, Strober S, Leventhal JR, et al. The Fourth International Workshop on Clinical Transplant Tolerance. Am J Transplant 2021;21:21-31. https://doi.org/10.1111/ajt.16139
  18. Johnson AC, Huang CA, Mathes DW. Tolerance protocols in large animal VCA models: comprehensive review. Curr Transplant Rep 2020;7:271-8.
  19. Devauchelle B, Badet L, Lengele B, et al. First human face allograft: early report. Lancet 2006;368:203-9. https://doi.org/10.1016/S0140-6736(06)68935-6
  20. Guo S, Han Y, Zhang X, et al. Human facial allotransplantation: a 2-year follow-up study. Lancet 2008;372:631-8. https://doi.org/10.1016/S0140-6736(08)61276-3
  21. Cavadas PC, Ibanez J, Thione A. Surgical aspects of a lower face, mandible, and tongue allotransplantation. J Reconstr Microsurg 2012;28:43-7. https://doi.org/10.1055/s-0031-1284236
  22. Dorafshar AH, Bojovic B, Christy MR, et al. Total face, double jaw, and tongue transplantation: an evolutionary concept. Plast Reconstr Surg 2013;131:241-51. https://doi.org/10.1097/PRS.0b013e3182789d38
  23. Sosin M, Ceradini DJ, Levine JP, et al. Total face, eyelids, ears, scalp, and skeletal subunit transplant: a reconstructive solution for the full face and total scalp burn. Plast Reconstr Surg 2016;138:205-19. https://doi.org/10.1097/PRS.0000000000002322
  24. Diaz-Siso JR, Fischer S, Sisk GC, et al. Initial experience of dual maintenance immunosuppression with steroid withdrawal in vascular composite tissue allotransplantation. Am J Transplant 2015;15:1421-31. https://doi.org/10.1111/ajt.13103
  25. Schneeberger S, Gorantla VS, Brandacher G, et al. Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. Ann Surg 2013;257:345-51. https://doi.org/10.1097/SLA.0b013e31826d90bb
  26. Grahammer J, Weissenbacher A, Zelger BG, et al. Benefits and limitations of belatacept in 4 hand-transplanted patients. Am J Transplant 2017;17:3228-35. https://doi.org/10.1111/ajt.14440
  27. Kaufman CL, Ouseph R, Blair B, et al. Graft vasculopathy in clinical hand transplantation. Am J Transplant 2012;12:1004-16. https://doi.org/10.1111/j.1600-6143.2011.03915.x
  28. Hautz T, Messner F, Weissenbacher A, et al. Long-term outcome after hand and forearm transplantation: a retrospective study. Transpl Int 2020;33:1762-78. https://doi.org/10.1111/tri.13752
  29. Uluer MC, Brazio PS, Woodall JD, et al. Vascularized composite allotransplantation: medical complications. Curr Transplant Rep 2016;3:395-403. https://doi.org/10.1007/s40472-016-0113-x
  30. Pomahac B, Pribaz J, Eriksson E, et al. Three patients with full facial transplantation. N Engl J Med 2012;366:715-22. https://doi.org/10.1056/NEJMoa1111432
  31. Schneeberger S, Kreczy A, Brandacher G, et al. Steroid- and ATG-resistant rejection after double forearm transplantation responds to Campath-1H. Am J Transplant 2004;4:1372-4. https://doi.org/10.1111/j.1600-6143.2004.00518.x
  32. Barret JP, Gavalda J, Bueno J, et al. Full face transplant: the first case report. Ann Surg 2011;254:252-6. https://doi.org/10.1097/SLA.0b013e318226a607
  33. Platt JL, Kaufman CL, Garcia de Mattos Barbosa M, et al. Accommodation and related conditions in vascularized composite allografts. Curr Opin Organ Transplant 2017;22:470-6. https://doi.org/10.1097/MOT.0000000000000446
  34. Morelon E, Petruzzo P, Kanitakis J, et al. Face transplantation: partial graft loss of the first case 10 years later. Am J Transplant 2017;17:1935-40. https://doi.org/10.1111/ajt.14218
  35. Gordon CR, Siemionow M, Papay F, et al. The world's experience with facial transplantation: what have we learned thus far? Ann Plast Surg 2009;63:572-8. https://doi.org/10.1097/SAP.0b013e3181ba5245
  36. Lian CG, Bueno EM, Granter SR, et al. Biomarker evaluation of face transplant rejection: association of donor T cells with target cell injury. Mod Pathol 2014;27:788-99. https://doi.org/10.1038/modpathol.2013.249
  37. Kollar B, Shubin A, Borges TJ, et al. Increased levels of circulating MMP3 correlate with severe rejection in face transplantation. Sci Rep 2018;8:14915. https://doi.org/10.1038/s41598-018-33272-7
  38. Honeyman C, Stark H, Wang HC, et al. Biomarker and surrogate development in vascularised composite allograft transplantation: current progress and future challenges. J Plast Reconstr Aesthet Surg 2021;74:711-7. https://doi.org/10.1016/j.bjps.2020.11.022
  39. Horner BM, Ferguson KK, Randolph MA, et al. In vivo observations of cell trafficking in allotransplanted vascularized skin flaps and conventional skin grafts. J Plast Reconstr Aesthet Surg 2010;63:711-9. https://doi.org/10.1016/j.bjps.2009.01.036
  40. Leonard DA, Amin KR, Giele H, et al. Skin immunology and rejection in VCA and organ transplantation. Curr Transplant Rep 2020;7:251-9. https://doi.org/10.1007/s40472-020-00310-1
  41. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008;358:353-61. https://doi.org/10.1056/NEJMoa071074
  42. Kawai T, Sachs DH, Sykes M, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2013;368:1850-2. https://doi.org/10.1056/NEJMc1213779
  43. Kawai T, Sachs DH, Sprangers B, et al. Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression. Am J Transplant 2014;14:1599-611. https://doi.org/10.1111/ajt.12731
  44. Busque S, Scandling JD, Lowsky R, et al. Mixed chimerism and acceptance of kidney transplants after immunosuppressive drug withdrawal. Sci Transl Med 2020;12:eaax8863. https://doi.org/10.1126/scitranslmed.aax8863
  45. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. Am J Transplant 2012;12:1133-45. https://doi.org/10.1111/j.1600-6143.2012.03992.x
  46. Scandling JD, Busque S, Shizuru JA, et al. Chimerism, graft survival, and withdrawal of immunosuppressive drugs in HLA matched and mismatched patients after living donor kidney and hematopoietic cell transplantation. Am J Transplant 2015;15:695-704. https://doi.org/10.1111/ajt.13091
  47. Leventhal J, Abecassis M, Miller J, et al. Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: durable chimerism predicts outcome. Transplantation 2013;95:169-76. https://doi.org/10.1097/TP.0b013e3182782fc1
  48. Leventhal J, Galvin J, Gallon L, et al. Ten year follow-up of a phase 2 clinical trial to induce tolerance in living donor renal transplant recipients. Am J Transplant 2019;19 (suppl 3): 541.
  49. Leventhal JR, Ildstad ST. Tolerance induction in HLA disparate living donor kidney transplantation by facilitating cell-enriched donor stem cell infusion: the importance of durable chimerism. Hum Immunol 2018;79:272-6. https://doi.org/10.1016/j.humimm.2018.01.007
  50. Lee KW, Park JB, Park H, et al. Inducing transient mixed chimerism for allograft survival without maintenance immunosuppression with combined kidney and bone marrow transplantation: protocol optimization. Transplantation 2020;104:1472-82. https://doi.org/10.1097/TP.0000000000003006
  51. Oh BC, Furtmuller GJ, Fryer ML, et al. Vascularized composite allotransplantation combined with costimulation blockade induces mixed chimerism and reveals intrinsic tolerogenic potential. JCI Insight 2020;5:e128560. https://doi.org/10.1172/jci.insight.128560
  52. Anggelia MR, Cheng HY, Chuang WY, et al. Unraveling the crucial roles of FoxP3+ regulatory T cells in vascularized composite allograft tolerance induction and maintenance. Transplantation 2021;105:1238-49. https://doi.org/10.1097/TP.0000000000003509
  53. Lellouch AG, Ng ZY, Rosales IA, et al. Toward development of the delayed tolerance induction protocol for vascularized composite allografts in nonhuman primates. Plast Reconstr Surg 2020;145:757e-768e. https://doi.org/10.1097/prs.0000000000006676
  54. Freitas AM, Samy KP, Farris AB, et al. Studies introducing costimulation blockade for vascularized composite allografts in nonhuman primates. Am J Transplant 2015;15:2240-9. https://doi.org/10.1111/ajt.13379
  55. Barth RN, Rodriguez ED, Mundinger GS, et al. Vascularized bone marrow-based immunosuppression inhibits rejection of vascularized composite allografts in nonhuman primates. Am J Transplant 2011;11:1407-16. https://doi.org/10.1111/j.1600-6143.2011.03551.x
  56. Brazio PS, Woodall J, Panda A, et al. Infused bone marrow fails to prevent vascularized composite allograft rejection in nonhuman primates. Am J Transplant 2015;15:2011-2. https://doi.org/10.1111/ajt.13268
  57. Hettiaratchy S, Melendy E, Randolph MA, et al. Tolerance to composite tissue allografts across a major histocompatibility barrier in miniature swine. Transplantation 2004;77:514-21. https://doi.org/10.1097/01.TP.0000113806.52063.42
  58. Horner BM, Randolph MA, Duran-Struuck R, et al. Induction of tolerance to an allogeneic skin flap transplant in a preclinical large animal model. Transplant Proc 2009;41:539-41. https://doi.org/10.1016/j.transproceed.2009.01.015
  59. Leonard DA, Kurtz JM, Mallard C, et al. Vascularized composite allograft tolerance across MHC barriers in a large animal model. Am J Transplant 2014;14:343-55. https://doi.org/10.1111/ajt.12560
  60. Chang J, Graves SS, Butts-Miwongtum T, et al. Long-term tolerance toward haploidentical vascularized composite allograft transplantation in a canine model using bone marrow or mobilized stem cells. Transplantation 2016;100:e120-7. https://doi.org/10.1097/TP.0000000000001496
  61. Sbano P, Cuccia A, Mazzanti B, et al. Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model. Arch Dermatol Res 2008;300:115-24. https://doi.org/10.1007/s00403-007-0827-9
  62. Kuo YR, Goto S, Shih HS, et al. Mesenchymal stem cells prolong composite tissue allotransplant survival in a swine model. Transplantation 2009;87:1769-77. https://doi.org/10.1097/TP.0b013e3181a664f1
  63. Kuo YR, Chen CC, Shih HS, et al. Prolongation of composite tissue allotransplant survival by treatment with bone marrow mesenchymal stem cells is correlated with T-cell regulation in a swine hind-limb model. Plast Reconstr Surg 2011;127:569-79. https://doi.org/10.1097/PRS.0b013e318200a92c
  64. Kuo YR, Chen CC, Chen YC, et al. Recipient adipose-derived stem cells enhance recipient cell engraftment and prolong allotransplant survival in a miniature swine hind-limb model. Cell Transplant 2017;26:1418-27. https://doi.org/10.1177/0963689717724534
  65. Siemionow M, Ozturk C. Face transplantation: outcomes, concerns, controversies, and future directions. J Craniofac Surg 2012;23:254-9. https://doi.org/10.1097/SCS.0b013e318241b920
  66. Morelon E, Petruzzo P, Kanitakis J. Chronic rejection in vascularized composite allotransplantation. Curr Opin Organ Transplant 2018;23:582-91. https://doi.org/10.1097/MOT.0000000000000571
  67. Tchiloemba B, Kauke M, Haug V, et al. Long-term outcomes after facial allotransplantation: systematic review of the literature. Transplantation 2021;105:1869-80. https://doi.org/10.1097/TP.0000000000003513
  68. Benedict J, Magill G. Upper extremity and craniofacial vascularized composite allotransplantation: ethics and immunosuppression. Emerg Top Life Sci 2019;3:681-6. https://doi.org/10.1042/etls20190060
  69. Brandacher G, Grahammer J, Sucher R, et al. Animal models for basic and translational research in reconstructive transplantation. Birth Defects Res C Embryo Today 2012;96:39-50. https://doi.org/10.1002/bdrc.21002
  70. Yamada Y, Ochiai T, Boskovic S, et al. Use of CTLA4Ig for induction of mixed chimerism and renal allograft tolerance in nonhuman primates. Am J Transplant 2014;14:2704-12. https://doi.org/10.1111/ajt.12936
  71. Wamala I, Matar AJ, Farkash E, et al. Recombinant anti-monkey CD3 immunotoxin depletes peripheral lymph node T lymphocytes more effectively than rabbit anti-thymocyte globulin in naive baboons. Transpl Immunol 2013;29:60-3. https://doi.org/10.1016/j.trim.2013.10.004
  72. Watanabe R, Gehad A, Yang C, et al. Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells. Sci Transl Med 2015;7:279ra39. https://doi.org/10.1126/scitranslmed.3010302
  73. Frankel AE, Woo JH, Ahn C, et al. Resimmune, an antiCD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma. Haematologica 2015;100:794-800. https://doi.org/10.3324/haematol.2015.123711
  74. Tedesco-Silva H, Pescovitz MD, Cibrik D, et al. Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. Transplantation 2006;82:1689-97. https://doi.org/10.1097/01.tp.0000251718.95622.b3
  75. Salvadori M, Budde K, Charpentier B, et al. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant 2006;6:2912-21. https://doi.org/10.1111/j.1600-6143.2006.01552.x
  76. Dun H, Song L, Ma A, et al. ASP0028 in combination with suboptimal-dose of tacrolimus in Cynomolgus monkey renal transplantation model. Transpl Immunol 2017;40:57-65. https://doi.org/10.1016/j.trim.2017.01.002